A time-of-drug addition approach to target identification of antiviral compounds.
about
Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical applicationThe lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applicationsThe root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitorThe Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal ApplicationsThe Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry InhibitionA core extended naphtalene diimide G-quadruplex ligand potently inhibits herpes simplex virus 1 replicationSmartphone-Based Fluorescent Diagnostic System for Highly Pathogenic H5N1 VirusesRapid screening of HIV reverse transcriptase and integrase inhibitors.Antiviral Activity of Oroxylin A against Coxsackievirus B3 Alleviates Virus-Induced Acute Pancreatic Damage in MiceHuman Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.Identification and characterization of a new type of inhibitor against the human immunodeficiency virus type-1 nucleocapsid protein.A phenyl-thiadiazolylidene-amine derivative ejects zinc from retroviral nucleocapsid zinc fingers and inactivates HIV virions.The Interferon Type I/III Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells Can Be Attenuated or Amplified by Antiviral TreatmentPotent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins.Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model.Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner.The feasibility of incorporating Vpx into lentiviral gene therapy vectors.Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage.Novel inhibitors of human immunodeficiency virus type 2 infectivity.Polymers fight HIV: potent (pro)drugs identified through parallel automated synthesis.2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors.The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway.Some hydrazones of 2-aroylamino-3-methylbutanohydrazide: synthesis, molecular modeling studies, and identification as stereoselective inhibitors of HIV-1.Antiviral effects of black raspberry (Rubus coreanus) seed extract and its polyphenolic compounds on norovirus surrogates.Anti-HIV-1 activity of the G-quadruplex ligand BRACO-19.Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication.Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro.Discovery of a semi-synthesized cyclolignan as a potent HIV-1 non-nucleoside reverse transcriptase inhibitor.G-quadruplexes and G-quadruplex ligands: targets and tools in antiviral therapy.Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate.Experimental Dissection of the Lytic Replication Cycles of Herpes Simplex Viruses
P2860
Q28486916-4FFD9F32-5A84-4672-84DE-196629993BDFQ28533345-74DB7E2F-4711-48CF-A233-304FFEA28AB9Q28539308-5EE4891F-A52B-46E7-9473-E7AC98BDF6D9Q28546014-180B6087-0A84-4AA7-9893-2B1E0B519678Q28552932-F48E7B99-F7C7-45E5-81F3-BA20DDFFB4D8Q30250926-9D71E086-35BE-433F-9C53-9FDE6CB8BD56Q33447235-19BF9843-E36A-4AFA-A62E-9AA7BA29C59DQ34193340-A9B5E5F7-10C8-4AB9-8100-0E27F2278259Q36022033-03610E3A-8BDD-461A-A007-2D249E006481Q36106299-92F47C7D-F782-408A-B7D0-72165AB526D5Q36256762-F1228E9B-F2BD-4E39-BE87-4CAEE1DFD741Q36523852-31CC6D94-F0E9-4FF0-9EB5-81B5DB10C6A8Q36523926-53D3C05B-DB7E-4E0B-9CBE-E39566C052F3Q36528651-DF4089D6-1658-4869-86A8-40744C953FCDQ36686322-E55B5D4D-305A-4F3C-B0D9-705F6A32DCADQ37057289-C2BE8896-53C2-4ED9-A1D0-295419B4AA32Q37350713-5599CCA1-CB8E-46C8-9645-897F68622043Q38729217-6C2D7C3C-6E79-41F9-9282-CD4461AF3212Q38967949-048FDB3A-AF87-45AA-8BD3-691EEF9AC477Q38996924-B61182C8-3034-4A74-B09E-2E6E72F19733Q39016799-FC266FF2-532F-4884-AF18-7B28AFCD8E62Q39029310-F2EE2D10-27BB-4890-9AC9-17FDB711790DQ39218058-ECF11C6B-84C6-43C6-B307-D56ABE61CA49Q40850255-45457C4E-4966-47B5-95FE-E1655A1E882AQ42201256-99A0022B-6781-4070-A9AC-47511FB0829BQ45324483-2D779BF4-338E-4745-A983-185205AEB0C2Q46103147-ACA3DDA7-6C51-4E6A-9E51-49A406DADA62Q47560158-2226FB83-93B9-4401-A8A2-2C32E69DAA49Q51336180-DB0F289E-5EB9-4468-A1AA-E312480C9E36Q53704198-E7AFC1D6-3043-474A-B546-5A43ABCEDDE8Q55015745-B9EEDF9C-5E62-46BE-A7A0-9E7CBEA236F7Q58572935-8BEF168F-45B0-47F0-9A66-7DB76A4726C1
P2860
A time-of-drug addition approach to target identification of antiviral compounds.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A time-of-drug addition approach to target identification of antiviral compounds.
@en
A time-of-drug addition approach to target identification of antiviral compounds.
@nl
type
label
A time-of-drug addition approach to target identification of antiviral compounds.
@en
A time-of-drug addition approach to target identification of antiviral compounds.
@nl
prefLabel
A time-of-drug addition approach to target identification of antiviral compounds.
@en
A time-of-drug addition approach to target identification of antiviral compounds.
@nl
P2860
P50
P356
P1433
P1476
A time-of-drug addition approach to target identification of antiviral compounds.
@en
P2093
Rudi Pauwels
P2860
P2888
P304
P356
10.1038/NPROT.2011.330
P577
2011-06-02T00:00:00Z